Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

DYN Dyne Therapeutics Inc

13,79

0,24 (1,77%)

26 Fev 2025 - Fechado

Atrasado em 15 minutos

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Dyne Therapeutics.

Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Dyne Therapeutics.

Notícias Dyne Therapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 25 de Fevereiro de 2025 (1 dia atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Terça, 18 de Fevereiro de 2025 (1 semana atrás) • Edgar (US Regulatory)

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Sexta, 14 de Fevereiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Segunda, 3 de Fevereiro de 2025 (3 semanas atrás) • GlobeNewswire Inc.

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Terça, 21 de Janeiro de 2025 (1 mês atrás) • GlobeNewswire Inc.

Form 8-K - Current report
Sexta, 10 de Janeiro de 2025 (2 meses atrás) • Edgar (US Regulatory)

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101
Sexta, 10 de Janeiro de 2025 (2 meses atrás) • GlobeNewswire Inc.

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Quinta, 9 de Janeiro de 2025 (2 meses atrás) • GlobeNewswire Inc.

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Quarta, 8 de Janeiro de 2025 (2 meses atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 11 de Dezembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quarta, 11 de Dezembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 10 de Dezembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Dyne Therapeutics Inc

Índice Bovespa

Azevedo & Travassos Ener... ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições